Expand all sections

Veliparib

Extended indication Breast cancer; HER2-negative metastatic or locally advanced unresectable BRCA-associated - first to
Therapeutic value No judgement
Registration phase Clinical trials

Product

Active substance Veliparib
Domain Oncology and Hematology
Main indication Breast cancer
Extended indication Breast cancer; HER2-negative metastatic or locally advanced unresectable BRCA-associated - first to third-line in combination with carboplatin and paclitaxel.
Manufacturer Abbvie
Route of administration Oral
Therapeutical formulation Capsule
Budgetting framework Intermural (MSZ)
Additional remarks PARP-remmer

Registration

Registration route Centralised (EMA)
Particularity New medicine
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Current treatment options Concurrentie van alle parp-remmers.
Therapeutic value No judgement

Expected patient volume per year

Patient volume

< 189

Market share is generally not included unless otherwise stated.
References NKR
Additional remarks NKR 2015: 1885 mammacarcinomen HER- stadia 3 en 4. 5-10% van borstkankers wordt veroorzakt door BRCA mutaties.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.